In this article, we provide an overview of preclinical evidence of crosstalk between the ER and HER2 cell signaling pathways, discuss the implications for targeted treatment of HR+/HER2+ breast cancer, and review new clinical evidence from randomized trials demonstrating enhanced antitumor activity with dual ER plus HER2 targeting in breast cancers. Here, HR is linked to breast carcinoma.